NVP-2, in combination with Orlistat, represents a promising therapeutic strategy for acute myeloid leukemia

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Cell cycle dysregulation and metabolic reprogramming are hallmarks of cancer, particularly in acute myeloid leukemia (AML).
• Cyclin-dependent kinase 9 (CDK9) plays a critical role in gene transcription and cell cycle regulation, and its aberrant activity contributes to oncogenesis in AML.
• The precise function of CDK9 in gene regulation and its impact on AML cell proliferation and survival warrant further investigation.

Purpose of the Study:

• To investigate the role of CDK9 in regulating gene expression, proliferation, and apoptosis in AML cells.
• To explore the combined therapeutic potential of targeting CDK9 and fatty acid synthase (FASN) in AML.

Main Methods:

• CDK9 was knocked down in U937 AML cells to assess its effects on cell growth and survival.
• RNA sequencing (RNA-seq) was employed to identify genes regulated by CDK9 in U937 cells.
• The proliferation and survival of Kasumi-1 and U937 cells were evaluated under combined treatment with NVP-2 (a CDK9 inhibitor) and Orlistat (a FASN inhibitor).

Main Results:

• CDK9 knockdown in U937 cells affected the expression of numerous genes involved in proliferation and apoptosis, including mTOR, SREBF1, and Bcl-2.
• Both CDK9 and FASN were identified as critical for the proliferation and survival of Kasumi-1 and U937 AML cell lines.
• Mechanistic insights suggest that MCL1, c-Myc, and the Akt/mTOR/SREBF1 pathway are key mediators in the combined efficacy of NVP-2 and Orlistat.

Conclusions:

• CDK9 and FASN are essential for maintaining the survival and proliferation of AML cells.
• Combined inhibition of CDK9 and FASN using NVP-2 and Orlistat represents a potentially effective therapeutic strategy for AML patients.